Evidence map›Paper›PMID 27054340›Full record

ArticlePloS one2016

Dexmedetomidine Inhibits Maturation and Function of Human Cord Blood-Derived Dendritic Cells by Interfering with Synthesis and Secretion of IL-12 and IL-23.

Gong Chen, Yuan Le, Lei Zhou, Li Gong, Xiaoxiao Li, Yunli Li, Qin Liao, Kaiming Duan, Jianbin Tong, Wen Ouyang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. ERK1/2 activation in anti-inflammatory effects and underlying signaling mechanisms.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Anesthesia and Oncology: Friend or Foe?Frontiers in oncology · 2022
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Gong ChenDepartment of Anesthesiology, the Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Yuan LeDepartment of Anesthesiology, the Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Lei ZhouDepartment of Anesthesiology, the Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Li GongDepartment of Anesthesiology, the Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xiaoxiao LiDepartment of Anesthesiology, the Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Yunli LiDepartment of Anesthesiology, the Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Qin LiaoDepartment of Anesthesiology, the Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Kaiming DuanDepartment of Anesthesiology, the Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Jianbin TongDepartment of Anesthesiology, the Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Wen OuyangDepartment of Anesthesiology, the Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Third Xiangya Hospital · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo investigate the effects and underlying mechanism of dexmedetomidine on the cultured human dendritic cells (DCs).

methodsHuman DCs and cytotoxic T lymphocytes (CTLs) were obtained from human cord blood mononuclear cells by density gradient centrifugation. Cultured DCs were divided into three groups: dexmedetomidine group, dexmedetomidine plus yohimbine (dexmedetomidine inhibitor) group and control group. DCs in the three groups were treated with dexmedetomidine, dexmedetomidine plus yohimbine and culture medium, respectively. After washing, the DCs were co-incubated with cultured CTLs. The maturation degree of DCs was evaluated by detecting (1) the ratios of HLA-DR-, CD86-, and CD80-positive cells (flow cytometry), and (2) expression of IL-12 and IL-23 (PCR and Elisa). The function of DCs was evaluated by detecting the proliferation (MTS assay) and cytotoxicity activity (the Elisa of IFN-γ) of CTLs. In addition, in order to explore the mechanisms of dexmedetomidine modulating DCs, α2-adrenergic receptor and its downstream signals in DCs were also detected.

resultsThe ratios of HLA-DR-, CD86-, and CD80-positive cells to total cells were similar among the three groups (P>0.05). Compared to the control group, the protein levels of IL-12 and IL-23 in the culture medium and the mRNA levels of IL-12 p35, IL-12 p40 and IL-23 p19 in the DCs all decreased in dexmedetomidine group (P<0.05). In addition, the proliferation of CTLs and the secretion of IFN-γ also decreased in the dexmedetomidine group, compared with the control group (P<0.05). Moreover, these changes induced by dexmedetomidine in the dexmedetomidine group were reversed by α2-adrenergic receptor inhibitor yohimbine in the dexmedetomidine plus yohimbine group. It was also found the decrease of mRNA levels of IL-12 p35, IL-12 p40 and IL-23 p19 in the dexmedetomidine group could be reversed by ERK1/2 or AKT inhibitors.

conclusionDexmedetomidine could negatively modulate human immunity by inhibiting the maturation of DCs and then decreasing the proliferation and cytotoxicity activity of CTLs. The α2-adrenergic receptors and its downstream molecules ERK1/2 and AKT are closely involved in the modulation of dexmedetomidine on DCs.

Indexed as

Adrenergic alpha-2 Receptor AgonistsBlotting, WesternCells, CulturedDendritic CellsDexmedetomidineFetal BloodHumansImmunophenotypingInterleukin-12Interleukin-23Real-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSignal TransductionT-Lymphocytes, CytotoxicAdrenergic alpha-2 Receptor AgonistsDexmedetomidineInterleukin-12Interleukin-23RNA, Messenger

Identifiers

PMID27054340
PMCPMC4824534
OpenAlexW2324321449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.